|
|
|
| Effects of Topiramate and Levetiracetam on Bone Metabolism in school-age Children with Epilepsy |
| LI Zhiyi |
| Ji'nan Children's Hospital, Shandong Ji'nan 250022, China |
|
|
|
|
Abstract Objective: To investigate the effects of topiramate and levetiracetam on the bone metabolism in children with school-age epilepsy. Methods: A total of 82 cases of children with school-age epilepsy who were treated in our hospital from October 2014 to October 2017 were randomly divided into group A and group B, 41 cases in each group. The two groups of children were treated with topiramate and levetiracetam, respectively. The clinical efficacy and the effect on bone metabolism were compared between the two groups. Results: The total effective rate of clinical treatment in group A and group B was 87.80% (36/41) and 90.24% (37/41) respectively, with no significant difference between the two groups (χ2 = 0.12, P> 0.05) The incidence of adverse reactions in group B was 46.34% (19/41) and 19.51% (8/41) respectively after treatment. The difference between the two groups was statistically significant (χ2 = 6.68, P <0.05). After treatment, The levels of Ca, P, ALP, BAP and BMD in group A were (2.46 ± 0.09) mmoL / L, 1.47 ± 0.07 mmoL / L, 183.68 ± 26.54 U / L, 232.64 ± 17.02 and 2.24 ± 1.72, respectively. The indexes in group B were [(2.46 ± 0.08) mmoL / L], [(184.12 ± 24.83) U / L], [(233.52 ± 18.31)] and [(2.26 ± 1.86) ]Before and after treatment, there was no significant difference between each index (P> 0.05). Conclusion: Topiramate and levetiracetam have a good therapeutic effect on children with school-age epilepsy, but the incidence of adverse reactions is high and safety is low during the course of topiramate treatment. However, the short-term use of the two drugs on the bone metabolism No obvious effect.
|
|
|
|
|
|
[1] 万令,雷华.左乙拉西坦添加治疗老年癫痫患者的临床观察[J].中国药房,2017,28(11):1516~1518.
[2] 王红梅,王晓慧,方方,等.左乙拉西坦口服液治疗儿童部分性癫痫的临床研究[J].中国临床药理学杂志,2016,32(19):1753~1755,1762.
[3] Brandt C,Lahr D,May T W.Cognitive adverse events of topiramate in patients with epilepsy and intellectual disability[J].Epilepsy Behav,2015,45:261~264.
[4] Wang Y Y,Wang M G,Yao D,et al.Comparison of impact on seizure frequency and epileptiform discharges of children with epilepsy from topiramate and phenobarbital[J].Eur Rev Med Pharmacol Sci,2016,20(5):993~997.
[5] Ruiz-Granados V J,Marquez-Romero J M.Topiramate in monotherapy or in combination as a cause of metabolic acidosis in adults with epilepsy[J].Rev Neurol,2015,60(4):159~163.
[6] 林岚,王晓燕,杨淑,等.丙戊酸钠联合左乙拉西坦治疗脑卒中后癫痫的临床观察[J].中国药房,2016,27(33):4634~4637.
[7] Takeuchi M,Yano I,Ito S,et al.Population pharmacokinetics of topiramate in Japanese pediatric and adult patients with epilepsy using routinely monitored data[J].Ther Drug Monit,2017,39(2):124~131.
[8] 聂磊,张涛,王海燕,等.左乙拉西坦对癫痫大鼠海马组织中5－HT2 A受体表达及其认知功能的影响[J].中国老年学杂志,2015,35(19):5415~5416,5417.
[9] Kato T,Nakata M,Ide M,et al.Efficacy and tolerability of topiramate,lamotrigine,and levetiracetam in children with refractory epilepsy[J].No To Hattatsu,2015,47(5):354~359. |
|
|
|
2018, Vol. 24 
